Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Revolution Medicines $750 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Cross Country Healthcare $615 million acquisition by Aya Healthcare
We are advising Cross Country Healthcare on the transaction
Laekna HK$236 million placement of shares
We advised Laekna on the placement of new shares
Alignment Healthcare $330 million convertible senior notes offering
The convertible notes are due 2029
ACELYRIN $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Cardinal Health $2.9 billion notes offering
The investment-grade notes are due 2026, 2029, 2034 and 2054
Omnicell $172.5 million convertible senior notes offering
The convertible senior notes are due 2029
Horizon Mutual Holdings debut $600 million senior notes offering
The investment-grade notes are due 2034
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction
Elevance Health $5.2 billion senior notes offering
The investment-grade notes are due 2026, 2030, 2031, 2035, 2055 and 2064